Congenital Abnormalities Clinical Trial
Official title:
Pattern Recognition and Anomaly Detection in Fetal Morphology Using Deep Learning and Statistical Learning
Congenital anomalies (CA) are the most encountered cause of fetal death, infant mortality and morbidity.7.9 million infants are born with CA yearly. Early detection of CA facilitates life-saving treatments and stops the progression of disabilities. CA can be diagnosed prenatally through Morphology Scan (MS). Discrepancies between pre and postnatal diagnosis of CA reach 29%. A correct interpretation of MS allows a detailed discussion regarding the prognosis with parents. The central feature of PARADISE is the development of a specialized intelligent system that embeds a committee of Deep Learning and Statistical Learning methods, which work together in a competitive/collaborative way to increase the performance of MS examinations by signaling CA. Using preclinical testing and clinical validation, the main goal will be the direct implementation into clinical practice. This multi-disciplinary project offers a unique integration of approaches, competences, breakthroughs in key applications in human, psychological, technological, and economical interest such as the 'smarter' healthcare system, opening new fields of research. PARADISE creates an environment that contributes significantly to the healthcare system, medical and pharma industries, scientific community, economy and ultimately to each individual. Its outcome will increase impact on the management of CA by enabling the establishment of detailed plans before birth, which will decrease morbidity and mortality in infants.
Probe guidance: The IS guides the sonographer's probe for better acquisition of the fetal biometric plane - Basic scanning to be performed by non-expert(> 90% accuracy (AC)) Fetal biometric plane finder: The fetal planes are automatically detected, measured and stored - Insurance that all anatomical parts are checked (100% AC) Anomaly detection: unusual findings are signaled - Assistance in decision making (>90% AC) ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05883761 -
Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
|
||
Completed |
NCT00766571 -
Clinical and Genetic Studies of VACTERL Association
|
||
Recruiting |
NCT05394363 -
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
|
||
Not yet recruiting |
NCT05393167 -
Congenital Anomalies in Infants of Diabetic Mother
|
||
Not yet recruiting |
NCT05547308 -
Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency
|
N/A | |
Recruiting |
NCT05151042 -
Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities
|
N/A | |
Recruiting |
NCT02505464 -
Pregnancies Complicated by Fetal Anomalies
|
||
Recruiting |
NCT02595307 -
Improving Informed Consent for Cleft Palate Repair
|
N/A | |
Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT00062452 -
Esophageal Motility and Airway Defenses Among Infants
|
N/A | |
Recruiting |
NCT05763615 -
3D Modeling of the Cervico-facial Region and Cranial Nerve Tractography: IMAG 2 ORL Project
|
N/A | |
Terminated |
NCT02351726 -
Mitroflow DL Post Approval Study- North America
|
N/A | |
Recruiting |
NCT04591392 -
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
|
N/A | |
Not yet recruiting |
NCT05231447 -
Birth Defect Registry in South West Region of France
|
||
Completed |
NCT01653392 -
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
|
||
Completed |
NCT02429947 -
An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients
|
N/A | |
Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT00362180 -
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
|
Phase 2 | |
Active, not recruiting |
NCT02987387 -
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
|
||
Completed |
NCT02875860 -
'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial
|
Phase 2 |